TY - JOUR
T1 - The Ninth Annual American Association for Cancer Research International Conference on Frontiers in Cancer Prevention Research
AU - Xu, Li
AU - Wang, Sophia S.
AU - Healey, Megan A.
AU - Faupel-Badger, Jessica M.
AU - Wilken, Jason A.
AU - Battaglia, Tracy
AU - Szabo, Eva
AU - Mao, Jenny T.
AU - Bergan, Raymond C.
PY - 2011/4
Y1 - 2011/4
N2 - The Ninth Annual AACR Frontiers in Cancer Prevention Research conference was held in Philadelphia in November 7-10, 2010. Its thematic focus was "Prevention: From Basic Science to Public Health Benefit." Telomere plasticity, the microenvironment, inflammation, transformation to the metastatic phenotype, and pathways to obesity were highlighted as important elements of carcinogenesis amenable to intervention. The integration of information from novel technologies related to physical biology, molecular and genetic profiles, and imaging along with behavioral and clinical parameters have advanced risk stratification and early detection. Cancer prevention represents a powerful testing ground for the development of individually tailored intervention and for increasing the efficiency of drug discovery. Advances in clinical trials relate to more efficient design strategies, have shown first-in-human targeting capabilities, and have developed powerful strategies to overcome accrual barriers. Tailored intervention strategies now show high efficacy on large cohorts across several cancer types. These successes are expected to increase.
AB - The Ninth Annual AACR Frontiers in Cancer Prevention Research conference was held in Philadelphia in November 7-10, 2010. Its thematic focus was "Prevention: From Basic Science to Public Health Benefit." Telomere plasticity, the microenvironment, inflammation, transformation to the metastatic phenotype, and pathways to obesity were highlighted as important elements of carcinogenesis amenable to intervention. The integration of information from novel technologies related to physical biology, molecular and genetic profiles, and imaging along with behavioral and clinical parameters have advanced risk stratification and early detection. Cancer prevention represents a powerful testing ground for the development of individually tailored intervention and for increasing the efficiency of drug discovery. Advances in clinical trials relate to more efficient design strategies, have shown first-in-human targeting capabilities, and have developed powerful strategies to overcome accrual barriers. Tailored intervention strategies now show high efficacy on large cohorts across several cancer types. These successes are expected to increase.
UR - http://www.scopus.com/inward/record.url?scp=79955854248&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955854248&partnerID=8YFLogxK
U2 - 10.1158/1940-6207.CAPR-11-0018
DO - 10.1158/1940-6207.CAPR-11-0018
M3 - Article
C2 - 21464034
AN - SCOPUS:79955854248
SN - 1940-6207
VL - 4
SP - 616
EP - 621
JO - Cancer Prevention Research
JF - Cancer Prevention Research
IS - 4
ER -